These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 24249759)

  • 21. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucagon-like peptide-1 agonists.
    Padwal R
    BMJ; 2012 Jan; 344():d7282. PubMed ID: 22236410
    [No Abstract]   [Full Text] [Related]  

  • 23. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.
    Su B; Sheng H; Zhang M; Bu L; Yang P; Li L; Li F; Sheng C; Han Y; Qu S; Wang J
    Endocrine; 2015 Feb; 48(1):107-15. PubMed ID: 25074632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects.
    Mundil D; Cameron-Vendrig A; Husain M
    Diab Vasc Dis Res; 2012 Apr; 9(2):95-108. PubMed ID: 22496442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liraglutide in the treatment of obesity.
    Ng SY; Wilding JP
    Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus.
    Harris KB; Boland CL
    Pharmacotherapy; 2016 Sep; 36(9):1011-20. PubMed ID: 27485823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
    Lorber D
    Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.
    Monami M; Cremasco F; Lamanna C; Colombi C; Desideri CM; Iacomelli I; Marchionni N; Mannucci E
    Exp Diabetes Res; 2011; 2011():215764. PubMed ID: 21584276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.
    Monami M; Dicembrini I; Marchionni N; Rotella CM; Mannucci E
    Exp Diabetes Res; 2012; 2012():672658. PubMed ID: 22675341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.
    McKay NJ; Kanoski SE; Hayes MR; Daniels D
    Am J Physiol Regul Integr Comp Physiol; 2011 Dec; 301(6):R1755-64. PubMed ID: 21975647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.
    Mul JD; Begg DP; Barrera JG; Li B; Matter EK; D'Alessio DA; Woods SC; Seeley RJ; Sandoval DA
    Am J Physiol Regul Integr Comp Physiol; 2013 Jul; 305(1):R68-77. PubMed ID: 23616105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.
    Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.
    Kanoski SE; Fortin SM; Arnold M; Grill HJ; Hayes MR
    Endocrinology; 2011 Aug; 152(8):3103-12. PubMed ID: 21693680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.
    Chiu WY; Shih SR; Tseng CH
    Exp Diabetes Res; 2012; 2012():924168. PubMed ID: 22693487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes.
    Ross SA
    Curr Med Res Opin; 2015 Jan; 31(1):125-35. PubMed ID: 25299351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An update in incretin-based therapy: a focus on glucagon-like peptide-1 receptor agonists.
    Edwards KL; Stapleton M; Weis J; Irons BK
    Diabetes Technol Ther; 2012 Oct; 14(10):951-67. PubMed ID: 22845681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.